Clinical Oncology
Volume 19, Issue 3 , Pages 182-187 , April 2007

The Role of Radiotherapy in the Treatment of Malignant Pleural Mesothelioma

  • K. Waite

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: K. Waite, Oncology Centre, Box 193, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. Tel: +44-01223-245151; Fax: +44-01223-274409.
    • ,
  • D. Gilligan

Received 22 September 2005 ,Revised 20 November 2006 ,Accepted 7 December 2006.

References 

  1. Hughes RS. Malignant pleural mesothelioma. Am J Med Sci. 2005;329:29–44
  2. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumours. In:  Sobin LH editors. World Health Organization international classification of tumours. Berlin: Springer; 1999;
  3. Peto J, Hodgson JT, Matthews FE, Jones J. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995;345:535–539
  4. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–672
  5. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723–731
  6. Burgers JA, Damhuis RAM. Prognostic factors in malignant mesothelioma. Lung Cancer. 2004;45(Suppl 1):S49–S54
  7. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145–152
  8. Van Gelder T, Damhuis RAM, Hoogsteden HC. Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J. 1994;7:1035–1038
  9. Law MR, Hodson ME, Turner-Warwick M. Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment. Eur J Respir Dis. 1984;65:162–168
  10. Gordon W, Antman KH, Greenberger JS, Weichselbaum RR, Chaffey JT. Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys. 1982;8:19–25
  11. Bissett D, Macbeth FR, Cram I. The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol). 1991;3:315–317
  12. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol. 1990;13:4–9
  13. De Graaf-Strukowska L, Van der Zee J, Van Putten W, Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura – a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys. 1999;43:511–516
  14. Van der Zee J, van de Pol M, Praag JO. Letter to the editor. Radiother Oncol. 2004;70:99
  15. Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. Australas Radiol. 1994;38:212–214
  16. British Thoracic Society Standards of Care Committee . Statement on malignant mesothelioma in the United Kingdom. Thorax. 2001;56:250–265
  17. Steele JPC, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol. 2005;16:345–351
  18. Steele JPC, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000;18:3912–3917
  19. Middleton GW, Smith IE, O'Brien MER, et al. Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol. 1998;9:269–273
  20. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  21. Gralla RJ, Hollen PJ, Liepa AM, et al. Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed+cisplatin vs cisplatin trial using the LCSS-meso instrument. Proc Am Soc Clin Oncol. 2003;22:621;(abstract 2496)
  22. Van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–6889
  23. Boutin C, Rey F, Viallat J-R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. Chest. 1995;108:754–758
  24. Low EM, Khoury GG, Matthews AW, Neville E. Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy. Clin Oncol (R Coll Radiol). 1995;7:317–318
  25. Bydder S, Phillips M, Joseph DJ, et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004;91:9–10
  26. De Bree E, van Ruth S, Bass P, et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest. 2002;121:480–487
  27. Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56:1319–1326
  28. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–795
  29. O'Rourke N, Curto Garcia J, McMenemin R, Hill J, Lawless C. A randomised controlled trial of radiotherapy to mesothelioma drain sites. Lung Cancer. 2005;49(Suppl 2):S226
  30. Pinto C, Sperandi F, Marino A, Mutri V, Martoni A. Is prophylactic radiotherapy necessary as prevention of tumor seeding following thoracoscopy in malignant pleural mesothelioma (MPM)?. Lung Cancer. 2005;49(Suppl 2):S227
  31. De Ruysscher D, Slotman B. Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch–Belgian survey. Radiother Oncol. 2003;68:299–302
  32. Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van Der Merwe CA. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol. 1988;6:527–535
  33. Law MR, Gregor A, Hodson ME, Bloom HJG, Turner-Warwick M. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax. 1984;39:255–259
  34. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest. 1995;107:332S–344S
  35. Maasilta P. Deterioration in lung function following hemithoracic irradiation for pleural mesothelioma. Int J Radiat Oncol Biol Phys. 1991;20:433–438
  36. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol. 2002;29:41–50
  37. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Thorax. 1976;31:15–24
  38. Parker C, Neville E. Lung cancer – 8: management of malignant mesothelioma. Thorax. 2003;58:809–813
  39. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1997;63:334–338
  40. Holsti LR, Pyrhönen S, Kajanti M, et al. Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncol. 1997;36:397–405
  41. Waller D. Malignant mesothelioma – British surgical strategies. Lung Cancer. 2004;45(Suppl 1):S81–S84
  42. Peckitt C, Piggott S, Sydenham M, Treasure T, Waller D, Peto J. The MARS (Mesothelioma and Radical Surgery) trial, comparing extra-pleural pneumonectomy (EPP) against no surgery within a trimodality context. Clin Oncol (R Coll Radiol). 2004;6(Suppl 1):S37
  43. Snee MP, Lilley J. Technique of radical postoperative radiotherapy after pneumonectomy for mesothelioma. Clin Oncol (R Coll Radiol). 2003;15:189–192
  44. Ahamad A, Stevens CW, Smythe WR, et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;55:768–775
  45. Forster KM, Smythe WR, Starkschall G, et al. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys. 2003;55:606–616
  46. Scholz C, Schulze C, Oelfke U, Bortfeld T. Development and clinical application of a fast superposition algorithm in radiation therapy. Radiother Oncol. 2003;69:79–90
  47. Zierhut D, Gutwein S, Münter MW, Woger H, Debus J. Radiation therapy of mesothelioma: the Heidelberg experience and future aspects. Lung Cancer. 2004;45(Suppl 1):S85–S91
  48. Senan S, van de Pol M. Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma. Lung Cancer. 2004;45(Suppl 1):S93–S96

PII: S0936-6555(06)00435-3

doi: 10.1016/j.clon.2006.12.006

Clinical Oncology
Volume 19, Issue 3 , Pages 182-187 , April 2007

Article Tools